Integra LifeSciences (NASDAQ: IART) reported Q1 EPS of $0.55, in-line with the analyst estimate of $0.55. Revenue for the quarter came in at $368.9 million versus the consensus estimate of $362.05 million.

GUIDANCE:

Integra LifeSciences sees FY2024 EPS of $3.01-$3.11, versus the consensus of $3.19. Integra LifeSciences sees FY2024 revenue of $1.682-1.687 billion, versus the consensus of $1.616 billion. The revenue range represents reported growth of 8.4% to 9.4%, with organic growth of 3.3% to 4.3%, reflecting the completion of the Acclarent acquisition and the removal of approximately $10 million of revenue from the relaunch of SurgiMend and PriMatrix beginning in the second half.

For the second quarter 2024, the Company expects reported revenues in the range of $411 million to $416 million versus the consensus of $395.8 million, representing reported growth of 7.8% to 9.1% and organic growth of 1.3% to 2.6%, reflecting the better than expected first quarter performance and the completion of the Acclarent acquisition. Adjusted earnings per diluted share are expected to be in the range of $0.60 to $0.65, versus the consensus of $0.74.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.